Logo

Prestige Collaborates with Dr. Reddy to Commercialize HD201, a Proposed Biosimilar to Herceptin for HER2 Positive Breast and Metastatic Gastric Cancer

Share this

Prestige Collaborates with Dr. Reddy to Commercialize HD201, a Proposed Biosimilar to Herceptin for HER2 Positive Breast and Metastatic Gastric Cancer

Shots:

 

  • Dr. Reddy gets exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia & will be responsible for local registrations, marketing, and sales in the licensed territories
  • Prestige BioPharma will be responsible for the commercial supply of HD201 from its manufacturing facilities in Osong, South Korea
  • Prestige BioPharma’s HD201 (trastuzumab) is a proposed biosimilar to Roche’s Herceptin and can be used for the treatment of HER2 positive breast and metastatic gastric cancer

Ref: Businesswire | Image: Prestige 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions